TSRL, Inc., Announces the Addition of Two Seasoned Drug Development Scientists to its Operation

Therapeutic Systems Laboratory (TSRL, Inc.), a biopharmaceutical company developing oral drug delivery solutions for anti-infective and cancer therapeutics, announces the addition of two seasoned drug development scientists to its operation.
Elke Lipka, PhD, MBA and Dawn Reyna, MS will add drug development and quality assurance breadth and depth to TSRL’s business.

Dr. Elke Lipka joined TSRL as Vice President of Business Development to develop and implement a sustainable competitive commercialization strategy for TSRL’s technology portfolio and oral drug delivery services. Dr. Lipka held a number of scientific and management positions of increasing responsibility at TSRL, Parke-Davis, Pfizer and Esperion Therapeutics. Her expertise includes pharmacokinetic, drug metabolism and drug safety scientific guidance to small molecule and biologics drug development programs. In addition, she brings strong skills in project management, establishment of strategic partnerships, and management of financial and operational business aspects to TSRL.

Mrs. Dawn Reyna recently joined TSRL as manager of quality assurance and brings more than 10 years of extensive quality control and auditing experience in both pharmaceutical and contract research organization settings to the company.  Prior to joining TSRL, Mrs. Reyna held a number of research quality assurance and QA management positions at Pfizer Global R&D and MPI Research. She has hosted numerous FDA inspections has an outstanding reputation as an organized leader that never fails to deliver results.